Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
March 11, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical...
Tonix Pharmaceuticals Announces New European Use Patent for TNX-601
March 07, 2019 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical...
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
March 01, 2019 17:41 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical...
Tonix Pharmaceuticals Announces Share Repurchase Program
March 01, 2019 16:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase...
Tonix Pharmaceuticals Announces New Board Member, James Treco
February 19, 2019 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Directors,...
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
February 04, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
January 02, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
December 18, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical...
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
December 11, 2018 16:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical...
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
December 07, 2018 10:35 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical...